Stock Market News2 weeks Beam Therapeutics’ Q4 Earnings & Revenues Beat Estimates Zacks
BEAM incurs a narrower-than-expected loss in the fourth quarter. The company remains focused on pipeline development.
XBEAM incurs a narrower-than-expected loss in the fourth quarter. The company remains focused on pipeline development.
X